<DOC>
	<DOCNO>NCT02107131</DOCNO>
	<brief_summary>Performance assessment test may useful tool evaluate impact ranibizumab day-to-day visual function patient Diabetic Macular Edema ( DME ) .</brief_summary>
	<brief_title>Performance Assessment Tests Working Individuals With DME Following Treatment With Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age 18 ≤ x ≤ 65 year currently employ baseline study visit Diagnosis diabetes mellitus ( type 1 2 ) Any one following consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes Current regular use oral antihyperglycemia agent treatment diabetes Clinical evidence retinal thickening due macular edema involve center macula , associate diabetic retinopathy . Central diabetic macular edema present clinical examination evidence indicate disease activity spectral domain OCT . Visual acuity score great equal 19 letter ( 20/400 ) less equal 73 letter ( 20/40 ) ETDRS visual acuity protocol . Media clarity , pupillary dilation patient cooperation sufficient allow OCT test retinal photography Pregnancy ( positive pregnancy test ) know pregnant ; also premenopausal woman use adequate contraception . Participation another ocular investigation trial simultaneously Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) Any condition , opinion investigator , would preclude participation study ( e.g . chronic alcoholism , drug abuse ) Evidence vitreoretinal interface abnormality ocular exam OCT may contribute macular edema An eye , investigator 's opinion , chance improve visual acuity follow resolution macular edema ( e.g . presence subretinal fibrosis geographic atrophy ) Presence another ocular condition may affect visual acuity macular edema course study ( e.g . AMD , uveitis , IrvineGas ) Evidence active neovascularization iris retina Evidence central atrophy fibrosis study eye Presence substantial cataract , one might decrease vision 3 line vision sometime study . Previous use intraocular periocular corticosteroid study eye previous 120 day Previous treatment antiangiogenic drug study eye i.e . pegaptanib sodium , bevacizumab , ranibizumab , aflibercept within 120 day prior baseline History vitreous surgery study eye History cataract surgery within 3 month enrollment . History YAG capsulotomy within 2 month enrollment . Visual acuity &lt; 20/400 fellow eye Uncontrolled glaucoma ( pressure &gt; 30 ) despite treatment glaucoma medication . History cerebral vascular accident myocardial infarction within 3 month prior Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>